MedWatch

”And we want to do it again and again and again”

Approval of the diabetes drug Lyxumia is just the first step for Zealand Pharma. Read the interview with CEO David Solomon, in which he talks about the future plans for the company and explains why “small is beautiful and comfort kills”.

Foto: Zealand Pharma/PR

The gloomy first day of the week became somewhat brighter for the mid-sized Danish biotech company, Zealand Pharma. The company’s drug darling, the GLP-1 Lyxumia, was finally approved for the European market.

“We have achieved something which is very difficult and valuable and important. And we want to do it again and again and again,” David Solomon, CEO of Zealand Pharma says, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier